Fig. 4
The cost-effectiveness acceptability curve of sacituzumab govitecan compared to chemotherapy in China. (Note: WTP, willingness to pay; QALY, quality-adjusted life-year)
Fig. 4 | Cost Effectiveness and Resource Allocation
The cost-effectiveness acceptability curve of sacituzumab govitecan compared to chemotherapy in China. (Note: WTP, willingness to pay; QALY, quality-adjusted life-year)